48
Menopause & HRT (Hormone Replacement Therapy) Doç. Dr. Gazi YILDIRIM Yeditepe Üniversitesi Hastanesi Kadın Hastalıkları ve Doğum AD

Doç. Dr. Gazi YILDIRIM Yeditepe Üniversitesi Hastanesi Kadın Hastalıkları ve Doğum AD

Embed Size (px)

Citation preview

  • Slide 1
  • Do. Dr. Gazi YILDIRIM Yeditepe niversitesi Hastanesi Kadn Hastalklar ve Doum AD
  • Slide 2
  • Reproductive Aging Process begins in embryonic life. 20 weeks gestation - 6 - 7 million follicles. At birth - 1.5-2 million follicles At menarche - 300,000- 400,000 follicles Follicular atresia continues throughout life. Follicular loss accelerates when the total number of follicles is ~25,000 When follicles are sufficiently depleted (
  • prevention of postmenopausal osteoporosis PRIMARY PREVENTION 1. HRT 2. SERMS 3. TIBOLONE 4. Biophosphonate SECONDARY PREVENTION 1. Biophosphonates 2. Calcitonin (>5 yrs menopause) 3. Teriparatide 46
  • Slide 47
  • Bisphosphonates Promotes bone formation and decreases bone resorption Mechanism of Action First line treatment for osteoporosis in both men and post- menopausal women 1 Application Approved in both sexes for the prevention and treatment of osteoporosis Aledronate 2, Risedronate 3 and Zoledronic Acid 4
  • Slide 48
  • DrugVertebral Fracture RR Hip Fracture RR Non- vertebral RR Route/ Frequency Indicated for which gender AlendronatePO/QDay, QWeek Women Men RisedronatePO/QDay, QWeek, QMonth Women Men IbandronateNE PO/QMonth IV/Q3Mont h Women Zoledronic Acid IV/QYearWomen Men RR = Risk ReductionNE = No effect demonstrated Bisphosphonates